Pramipexole

Generic Name
Pramipexole
Brand Names
Mirapex, Mirapexin, Sifrol, Pramipexole Teva, Oprymea
Drug Type
Small Molecule
Chemical Formula
C10H17N3S
CAS Number
104632-26-0
Unique Ingredient Identifier
83619PEU5T
Background

Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a non-ergot dopamine agonist drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) . It was first approved by the FDA in 1997 . Parkinson's Disease is one of the most common neurodegenerative disorders and...

Indication

This drug is indicated for the symptomatic treatment of Parkinson’s disease . This drug can be administered as monotherapy or in conjunction with levodopa. It is also indicated for symptomatic treatment of moderate to severe primary Restless Legs Syndrome (RLS) .

Associated Conditions
Moderate restless legs syndrome (RLS), Parkinson's Disease (PD), Severe restless legs syndrome (RLS)
Associated Therapies
-
Clinical Trials
Related News

Pramipexole for Restless Leg Syndrome in Peritoneal Dialysis Patients

Phase 4
Terminated
Conditions
Restless Legs Syndrome
Interventions
Other: placebo
Drug: Pramipexole
First Posted Date
2019-01-25
Last Posted Date
2021-12-09
Lead Sponsor
Dong Jie
Target Recruit Count
21
Registration Number
NCT03817554
Locations
🇨🇳

Peking University First Hospital, Beijing, China

Pramipexole and Emotional Processing

Not Applicable
Completed
Conditions
Reward
Emotions
Motivation
Dopamine
Interventions
Drug: Placebo
Drug: Pramipexole
First Posted Date
2018-09-24
Last Posted Date
2020-03-24
Lead Sponsor
University of Oxford
Target Recruit Count
43
Registration Number
NCT03681509
Locations
🇬🇧

Dept of Psychiatry, University of Oxford, Oxford, Oxfordshire, United Kingdom

a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics

First Posted Date
2018-02-13
Last Posted Date
2022-06-27
Lead Sponsor
Shanghai Mental Health Center
Target Recruit Count
50
Registration Number
NCT03430596
Locations
🇨🇳

Shanghai Mental Health Center, Shanghai, Shanghai, China

Targeting Cognition in Bipolar Disorder With Pramipexole

Phase 4
Completed
Conditions
Bipolar Disorder
Interventions
Drug: Placebo
Drug: Pramipexole
First Posted Date
2015-03-25
Last Posted Date
2020-02-28
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
103
Registration Number
NCT02397837
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇺🇸

The Zucker Hillside Hospital, Glen Oaks, New York, United States

🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

Post Marketing Surveillance Study of Sifrol® in Patients With Idiopathic Parkinson's Disease

Completed
Conditions
Parkinson Disease
Interventions
Drug: Pramipexole
First Posted Date
2014-09-25
Last Posted Date
2014-09-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
442
Registration Number
NCT02248181

Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)

Completed
Conditions
Restless Legs Syndrome
Interventions
Drug: Pramipexole
First Posted Date
2014-09-25
Last Posted Date
2014-09-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1029
Registration Number
NCT02248142

Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease

Completed
Conditions
Parkinson Disease
Interventions
Drug: Pramipexole
First Posted Date
2014-09-25
Last Posted Date
2014-09-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
657
Registration Number
NCT02248220

Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease

Completed
Conditions
Parkinson Disease
Interventions
Drug: Pramipexole
First Posted Date
2014-09-25
Last Posted Date
2014-09-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1449
Registration Number
NCT02248168

Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease

Completed
Conditions
Parkinson Disease
Interventions
Drug: Pramipexole
First Posted Date
2014-09-25
Last Posted Date
2014-09-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1293
Registration Number
NCT02248207

Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)

Completed
Conditions
Restless Legs Syndrome
Interventions
Drug: Pramipexole
First Posted Date
2014-09-25
Last Posted Date
2014-09-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
2644
Registration Number
NCT02248155
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy